Functionally Closed Purification and Elution of Untouched Cells using Cleavable Magnetic Beads with Digital Magnetic Sorting

使用可裂解磁珠和数字磁分选对未接触的细胞进行功能封闭纯化和洗脱

• 批准号: 10603997
• 负责人: Coleman Murray
• 金额: $ 92.14万
• 依托单位: FERROLOGIX, INC.
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-02-01 至 2025-01-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10603997
• 关键词: Address; Allogenic; Autologous; Benchmarking; Cell Count; Cell Separation; Cell Survival; Cell Therapy; Cell physiology; Cells; Cleaved cell; Development; Devices; Environment; Excision; Goals; Hour; Interview; Learning; Magnetism; Methods; Monitor; Morphologic artifacts; Phase; Population; Process; Production; Reagent; Sampling; Sorting; Sterility; Surface; System; T-Lymphocyte; Technology; Therapeutic; Time; cell type; digital; imaging system; large scale production; magnetic beads; manufacture; next generation; operation; parallelization; scale up

Project Summary Isolation of specific and well-defined cell types to produce next generation cellular therapies remains a significant scale up and scale out challenge for autologous and allogeneic therapies. Through primary customer interviews of cell therapy developers, we learned there is an unmet need for scalable cell sorting systems that can isolate rare cell types on multiple markers in production of nuanced cellular therapeutics. With preliminary studies, we demonstrated that our scalable core technology (digital magnetic sorting) achieves superior rare cell isolation and can achieve parallelized multitarget sorting to address this need. In this proposal, we aim to develop a functionally closed, quantitative cell purification system that can isolate rare and specific cell types based on multiple markers at throughputs conducive for cell therapy manufacturing.

项目概要 分离特定且明确的细胞类型以产生下一代细胞疗法仍然需要显着扩大规模 并扩大自体和同种异体疗法的挑战。 通过对细胞疗法开发商的主要客户访谈，我们了解到可扩展细胞分选的需求尚未得到满足 可以在多种标记物上分离稀有细胞类型的系统，以生产细致入微的细胞疗法。与初步 研究中，我们证明了我们的可扩展核心技术（数字磁力分选）实现了卓越的稀有细胞分离 并且可以实现并行多目标排序来解决这一需求。 在本提案中，我们的目标是开发一种功能封闭的定量细胞纯化系统，可以分离稀有和 基于多种标记的特定细胞类型，吞吐量有利于细胞疗法的生产。